Drug-based therapy for advanced adenoid cystic carcinoma : current landscape and challenges based on an overview of registered clinical trials
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UFRGS |
Texto Completo: | http://hdl.handle.net/10183/271142 |
Resumo: | Adenoid cystic carcinoma (ACC) has a significant patient-population in need of effective systemic therapy, as no drug is currently approved by the FDA for its management. We critically reviewed ACC-clinical trials (CT) registered on the ClinicalTrials.gov website using “ACC” under condition or disease. Trials specifically designed to test a drug-based therapy for ACC (n = 33) were analyzed with most being one-arm phase II trials enrolling advanced, recurrent/metastatic, incurable ACC cases. Site restriction, maximum ECOG status, and period of disease progression varied as inclusion criteria. Small-molecule inhibitors were those most commonly investigated with Apatinib, Axitinib and Lenvatinib showing the best results in association with rigid enrollment criteria. The overall median time to progression remains modest and more efforts are urgently needed in this field. CTs designed to test drugs that act on key pathways associated with ACC aggressiveness are being conducted and represent a promising pathway if efficacy is proved. |
id |
UFRGS-2_dba42b8f98191073077b47b94e416266 |
---|---|
oai_identifier_str |
oai:www.lume.ufrgs.br:10183/271142 |
network_acronym_str |
UFRGS-2 |
network_name_str |
Repositório Institucional da UFRGS |
repository_id_str |
|
spelling |
Wagner, Vivian PetersenFerrarotto, RenataVargas, Pablo AgustinMartins, Manoela DominguesBingle, Colin D.Bingle, Lynne2024-01-26T04:45:47Z20231040-8428http://hdl.handle.net/10183/271142001194888Adenoid cystic carcinoma (ACC) has a significant patient-population in need of effective systemic therapy, as no drug is currently approved by the FDA for its management. We critically reviewed ACC-clinical trials (CT) registered on the ClinicalTrials.gov website using “ACC” under condition or disease. Trials specifically designed to test a drug-based therapy for ACC (n = 33) were analyzed with most being one-arm phase II trials enrolling advanced, recurrent/metastatic, incurable ACC cases. Site restriction, maximum ECOG status, and period of disease progression varied as inclusion criteria. Small-molecule inhibitors were those most commonly investigated with Apatinib, Axitinib and Lenvatinib showing the best results in association with rigid enrollment criteria. The overall median time to progression remains modest and more efforts are urgently needed in this field. CTs designed to test drugs that act on key pathways associated with ACC aggressiveness are being conducted and represent a promising pathway if efficacy is proved.application/pdfengCritical reviews in oncology/hematology. Amsterdam. Vol. 181 (Jan. 2023), 103886, 12 p.Neoplasias de cabeça e pescoçoNeoplasias das glandulas salivaresTratamento farmacológicoCarcinoma adenoide císticoHead and neck cancerSalivary gland cancerOncologyChemotherapyDrug-based therapy for advanced adenoid cystic carcinoma : current landscape and challenges based on an overview of registered clinical trialsEstrangeiroinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFRGSinstname:Universidade Federal do Rio Grande do Sul (UFRGS)instacron:UFRGSTEXT001194888.pdf.txt001194888.pdf.txtExtracted Texttext/plain89762http://www.lume.ufrgs.br/bitstream/10183/271142/2/001194888.pdf.txtde7f75ba1763d22afb8328a0debc092fMD52ORIGINAL001194888.pdfTexto completo (inglês)application/pdf792605http://www.lume.ufrgs.br/bitstream/10183/271142/1/001194888.pdf1c8b04f415342d77a7b1361a40aeeeffMD5110183/2711422024-01-27 06:01:22.092841oai:www.lume.ufrgs.br:10183/271142Repositório de PublicaçõesPUBhttps://lume.ufrgs.br/oai/requestopendoar:2024-01-27T08:01:22Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS)false |
dc.title.pt_BR.fl_str_mv |
Drug-based therapy for advanced adenoid cystic carcinoma : current landscape and challenges based on an overview of registered clinical trials |
title |
Drug-based therapy for advanced adenoid cystic carcinoma : current landscape and challenges based on an overview of registered clinical trials |
spellingShingle |
Drug-based therapy for advanced adenoid cystic carcinoma : current landscape and challenges based on an overview of registered clinical trials Wagner, Vivian Petersen Neoplasias de cabeça e pescoço Neoplasias das glandulas salivares Tratamento farmacológico Carcinoma adenoide cístico Head and neck cancer Salivary gland cancer Oncology Chemotherapy |
title_short |
Drug-based therapy for advanced adenoid cystic carcinoma : current landscape and challenges based on an overview of registered clinical trials |
title_full |
Drug-based therapy for advanced adenoid cystic carcinoma : current landscape and challenges based on an overview of registered clinical trials |
title_fullStr |
Drug-based therapy for advanced adenoid cystic carcinoma : current landscape and challenges based on an overview of registered clinical trials |
title_full_unstemmed |
Drug-based therapy for advanced adenoid cystic carcinoma : current landscape and challenges based on an overview of registered clinical trials |
title_sort |
Drug-based therapy for advanced adenoid cystic carcinoma : current landscape and challenges based on an overview of registered clinical trials |
author |
Wagner, Vivian Petersen |
author_facet |
Wagner, Vivian Petersen Ferrarotto, Renata Vargas, Pablo Agustin Martins, Manoela Domingues Bingle, Colin D. Bingle, Lynne |
author_role |
author |
author2 |
Ferrarotto, Renata Vargas, Pablo Agustin Martins, Manoela Domingues Bingle, Colin D. Bingle, Lynne |
author2_role |
author author author author author |
dc.contributor.author.fl_str_mv |
Wagner, Vivian Petersen Ferrarotto, Renata Vargas, Pablo Agustin Martins, Manoela Domingues Bingle, Colin D. Bingle, Lynne |
dc.subject.por.fl_str_mv |
Neoplasias de cabeça e pescoço Neoplasias das glandulas salivares Tratamento farmacológico Carcinoma adenoide cístico |
topic |
Neoplasias de cabeça e pescoço Neoplasias das glandulas salivares Tratamento farmacológico Carcinoma adenoide cístico Head and neck cancer Salivary gland cancer Oncology Chemotherapy |
dc.subject.eng.fl_str_mv |
Head and neck cancer Salivary gland cancer Oncology Chemotherapy |
description |
Adenoid cystic carcinoma (ACC) has a significant patient-population in need of effective systemic therapy, as no drug is currently approved by the FDA for its management. We critically reviewed ACC-clinical trials (CT) registered on the ClinicalTrials.gov website using “ACC” under condition or disease. Trials specifically designed to test a drug-based therapy for ACC (n = 33) were analyzed with most being one-arm phase II trials enrolling advanced, recurrent/metastatic, incurable ACC cases. Site restriction, maximum ECOG status, and period of disease progression varied as inclusion criteria. Small-molecule inhibitors were those most commonly investigated with Apatinib, Axitinib and Lenvatinib showing the best results in association with rigid enrollment criteria. The overall median time to progression remains modest and more efforts are urgently needed in this field. CTs designed to test drugs that act on key pathways associated with ACC aggressiveness are being conducted and represent a promising pathway if efficacy is proved. |
publishDate |
2023 |
dc.date.issued.fl_str_mv |
2023 |
dc.date.accessioned.fl_str_mv |
2024-01-26T04:45:47Z |
dc.type.driver.fl_str_mv |
Estrangeiro info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10183/271142 |
dc.identifier.issn.pt_BR.fl_str_mv |
1040-8428 |
dc.identifier.nrb.pt_BR.fl_str_mv |
001194888 |
identifier_str_mv |
1040-8428 001194888 |
url |
http://hdl.handle.net/10183/271142 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.pt_BR.fl_str_mv |
Critical reviews in oncology/hematology. Amsterdam. Vol. 181 (Jan. 2023), 103886, 12 p. |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFRGS instname:Universidade Federal do Rio Grande do Sul (UFRGS) instacron:UFRGS |
instname_str |
Universidade Federal do Rio Grande do Sul (UFRGS) |
instacron_str |
UFRGS |
institution |
UFRGS |
reponame_str |
Repositório Institucional da UFRGS |
collection |
Repositório Institucional da UFRGS |
bitstream.url.fl_str_mv |
http://www.lume.ufrgs.br/bitstream/10183/271142/2/001194888.pdf.txt http://www.lume.ufrgs.br/bitstream/10183/271142/1/001194888.pdf |
bitstream.checksum.fl_str_mv |
de7f75ba1763d22afb8328a0debc092f 1c8b04f415342d77a7b1361a40aeeeff |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFRGS - Universidade Federal do Rio Grande do Sul (UFRGS) |
repository.mail.fl_str_mv |
|
_version_ |
1801225109750415360 |